Keyword: Campath multiple sclerosis

News

Sanofi Says Gains Control Of Genzyme

04.04.2011 - French drugmaker Sanofi-Aventis completed its improved $20.1 billion offer for Genzyme allowing it to begin merging the U.S. biotech into its business and add rare diseases to its...

News

Sanofi CVRs Tied To Genzyme May Start Trading April 4

30.03.2011 - Certificates related to Sanofi-Aventis's $20.1 billion acquisition of U.S. biotech firm Genzyme could begin trading on Nasdaq as soon as April 4, depending on the outcome of its...

News

Henri Termeer To Leave Genzyme With About $160 Million

08.03.2011 - Genzyme Chief Executive Henri Termeer is set to walk away with nearly $160 million when the sale of his company to French drugmaker Sanofi-Aventis is final - and stands to earn...

News

Sanofi Could Announce Genzyme Deal Next Week

03.02.2011 - French drugmaker Sanofi-Aventis could announce a deal to buy U.S. biotech Genzyme early next week if final negotiations between the companies go smoothly, Le Figaro reported on...

News

Sanofi Puts Genzyme At Low $70s Plus Payout

02.02.2011 - France's Sanofi-Aventis has agreed to raise its bid for Genzyme Corp to the low $70s-per-share range, plus a milestone payment based on the performance of an experimental drug, a...

News

Genzyme, Sanofi Reach Agreement in Principle on Takeover Terms

01.02.2011 - U.S. biotech Genzyme and French drugmaker Sanofi-Aventis have reached agreement in principle on the terms of a deal under which Sanofi would acquire Genzyme, three sources familiar...

News

Genzyme CEO Says Proxy Fight Not Likely

27.01.2011 - A proxy battle for control of Genzyme is unlikely, given the progress being made in discussions with Sanofi-Aventis, the U.S. biotech group's chief executive said on Thursday...

News

Sanofi's Chris Viehbacher Sees Progress in Genzyme Talks

27.01.2011 - Sanofi-Aventis has made progress in talks with U.S. bid target Genzyme and leaders of both companies may bump into each other in Davos this week, Sanofi's CEO said on Wednesday...